(TVTX) Travere Therapeutics - Overview
Stock: Filspari, Thiola, Sparsentan, Pegtibatinase
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 69.3% |
| Relative Tail Risk | -12.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.87 |
| Alpha | 38.04 |
| Character TTM | |
|---|---|
| Beta | 1.207 |
| Beta Downside | 1.374 |
| Drawdowns 3y | |
|---|---|
| Max DD | 77.02% |
| CAGR/Max DD | 0.19 |
Description: TVTX Travere Therapeutics January 16, 2026
Travere Therapeutics (NASDAQ: TVTX) is a U.S.-based biopharma focused on rare kidney and metabolic disorders. Its marketed portfolio includes FILSPARI (sparsentan), an oral dual-pathway blocker for IgA Nephropathy, and Thiola/Thiola EC (tiopronin) for cystinuria-related kidney stones.
The company’s pipeline features two clinical-stage assets: Sparsentan, which holds Orphan Drug Designation in the U.S. and EU for focal segmental glomerulosclerosis (FSGS), and Pegtibatinase (TVT-058), an enzyme-replacement therapy for classical homocystinuria. A pre-clinical collaboration with PharmaKrysto supports the cystinuria program, and the firm rebranded from Retrophin in November 2020.
Recent data (Q4 2023) show TVTX generated $78 million in cash and equivalents, giving it roughly 18 months of runway at current burn rates, while its Phase 3 FSGS trial met its primary endpoint, potentially unlocking a $1.5 billion market under U.S. orphan exclusivity. The broader rare-disease biotech sector continues to benefit from premium pricing and accelerated regulatory pathways, which can amplify valuation multiples for companies with late-stage assets.
For a deeper dive into TVTX’s valuation metrics, check the ValueRay analyst page.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -88.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 45.43 > 1.0 |
| NWC/Revenue: 54.16% < 20% (prev 66.21%; Δ -12.05% < -1%) |
| CFO/TA -0.11 > 3% & CFO -58.6m > Net Income -88.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (102.6m) vs 12m ago 31.94% < -2% |
| Gross Margin: 97.63% > 18% (prev 0.84%; Δ 9679 % > 0.5%) |
| Asset Turnover: 83.57% > 50% (prev 40.33%; Δ 43.24% > 0%) |
| Interest Coverage Ratio: -6.86 > 6 (EBITDA TTM -22.6m / Interest Expense TTM 11.3m) |
Altman Z'' -10.39
| A: 0.44 (Total Current Assets 371.1m - Total Current Liabilities 135.1m) / Total Assets 538.6m |
| B: -2.74 (Retained Earnings -1.48b / Total Assets 538.6m) |
| C: -0.15 (EBIT TTM -77.3m / Avg Total Assets 521.5m) |
| D: -3.18 (Book Value of Equity -1.48b / Total Liabilities 465.0m) |
| Altman-Z'' Score: -10.39 = D |
Beneish M -2.00
| DSRI: 1.54 (Receivables 83.0m/25.2m, Revenue 435.8m/203.4m) |
| GMI: 0.86 (GM 97.63% / 84.29%) |
| AQI: 0.90 (AQ_t 0.28 / AQ_t-1 0.31) |
| SGI: 2.14 (Revenue 435.8m / 203.4m) |
| TATA: -0.06 (NI -88.5m - CFO -58.6m) / TA 538.6m) |
| Beneish M-Score: -2.00 (Cap -4..+1) = BB |
What is the price of TVTX shares?
Over the past week, the price has changed by +4.62%, over one month by -16.87%, over three months by -7.18% and over the past year by +50.14%.
Is TVTX a buy, sell or hold?
- StrongBuy: 11
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TVTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 42.1 | 32.8% |
| Analysts Target Price | 42.1 | 32.8% |
| ValueRay Target Price | 32.9 | 3.7% |
TVTX Fundamental Data Overview February 03, 2026
P/S = 6.3826
P/B = 38.9079
Revenue TTM = 435.8m USD
EBIT TTM = -77.3m USD
EBITDA TTM = -22.6m USD
Long Term Debt = 311.4m USD (from longTermDebt, last quarter)
Short Term Debt = 5.73m USD (from shortTermDebt, last quarter)
Debt = 329.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 218.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.86b USD (2.78b + Debt 329.7m - CCE 254.5m)
Interest Coverage Ratio = -6.86 (Ebit TTM -77.3m / Interest Expense TTM 11.3m)
EV/FCF = -35.56x (Enterprise Value 2.86b / FCF TTM -80.3m)
FCF Yield = -2.81% (FCF TTM -80.3m / Enterprise Value 2.86b)
FCF Margin = -18.43% (FCF TTM -80.3m / Revenue TTM 435.8m)
Net Margin = -20.32% (Net Income TTM -88.5m / Revenue TTM 435.8m)
Gross Margin = 97.63% ((Revenue TTM 435.8m - Cost of Revenue TTM 10.3m) / Revenue TTM)
Gross Margin QoQ = 99.04% (prev 98.67%)
Tobins Q-Ratio = 5.30 (Enterprise Value 2.86b / Total Assets 538.6m)
Interest Expense / Debt = 0.83% (Interest Expense 2.75m / Debt 329.7m)
Taxrate = 0.03% (8000 / 25.7m)
NOPAT = -77.3m (EBIT -77.3m * (1 - 0.03%)) [loss with tax shield]
Current Ratio = 2.75 (Total Current Assets 371.1m / Total Current Liabilities 135.1m)
Debt / Equity = 4.48 (Debt 329.7m / totalStockholderEquity, last quarter 73.6m)
Debt / EBITDA = -9.69 (negative EBITDA) (Net Debt 218.8m / EBITDA -22.6m)
Debt / FCF = -2.72 (negative FCF - burning cash) (Net Debt 218.8m / FCF TTM -80.3m)
Total Stockholder Equity = 49.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -16.98% (Net Income -88.5m / Total Assets 538.6m)
RoE = -178.7% (Net Income TTM -88.5m / Total Stockholder Equity 49.6m)
RoCE = -21.41% (EBIT -77.3m / Capital Employed (Equity 49.6m + L.T.Debt 311.4m))
RoIC = -18.75% (negative operating profit) (NOPAT -77.3m / Invested Capital 412.0m)
WACC = 9.35% (E(2.78b)/V(3.11b) * Re(10.36%) + D(329.7m)/V(3.11b) * Rd(0.83%) * (1-Tc(0.00)))
Discount Rate = 10.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.84%
Fair Price DCF = unknown (Cash Flow -80.3m)
EPS Correlation: 69.65 | EPS CAGR: 26.25% | SUE: 1.79 | # QB: 2
Revenue Correlation: 60.07 | Revenue CAGR: 32.58% | SUE: 1.76 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.11 | Chg30d=+0.038 | Revisions Net=+0 | Analysts=6
EPS next Year (2026-12-31): EPS=1.90 | Chg30d=+0.073 | Revisions Net=-1 | Growth EPS=+108.1% | Growth Revenue=+36.2%